J. G. Hardman and L. E. Limbird, Mc Graw-Hill. Les bases pharmacologiques de l'utilisation des médicaments 9 ème Edition. International Ltd, pp.881-900, 1998.

G. Bertram and S. P. Katzung, Pharmacologie fondamentale et clinique 7 ème Edition, pp.583-596, 2000.

M. Schorderet, Pharmacologie des concepts fondamentaux aux applications thérapeutiques. Edition Frisson-Roche, pp.555-565, 1998.

H. Autorité and D. Santé, Efficacité et efficience des hypolipémiants : une analyse centrée sur les statines. Evaluation des technologies de santé analyse médico-économique, 2010.

J. Cambou, J. Ferrieres, J. Ruidavets, and P. Ducimetiere, Epidemiology according to the European and French scales of myocardial infarction. Data of the MONICA project, Arch Mal Coeur Vaiss, vol.89, issue.3, pp.13-21, 1996.

M. Ciruzzi, H. Schargrodsky, J. Rozlosnik, P. Pramparo, H. Delmonte et al., Frequency of Family History of Acute Myocardial Infarction in Patients With Acute Myocardial Infarction, Argentine FRICAS (Factores de Riesgo Coronario en America del Sur) Investigators, pp.122-129, 1997.
DOI : 10.1016/S0002-9149(97)00304-4

M. Andresdottir, G. Sigurdsson, H. Sigvaldason, and V. Gudnason, Fifteen percent of myocardial infarctions and coronary revascularizations explained by family history unrelated to conventional risk factors. The Reykjavik Cohort Study, European Heart Journal, vol.23, issue.21, pp.1655-63, 2002.
DOI : 10.1053/euhj.2002.3235

A. Dobson, H. Alexander, R. Heller, and D. Lloyd, How soon after quitting smoking does risk of heart attack decline?, Journal of Clinical Epidemiology, vol.44, issue.11, pp.1247-53, 1991.
DOI : 10.1016/0895-4356(91)90157-5

P. Mcelduff, A. Dobson, R. Beaglehole, and R. Jackson, Rapid reduction in coronary risk for those who quit cigarette smoking, Australian and New Zealand Journal of Public Health, vol.97, issue.1, pp.787-91, 1998.
DOI : 10.1111/j.1467-842X.1998.tb01494.x

A. Nationale-d, Accréditation et d'Évaluation en Santé Prise en charge des patients adultes atteints d'hypertension artérielle essentielle. Recommandations cliniques et données économiques, 2000.

A. Grimaldi and A. Heurtier, Epidemiology of cardio-vascular complications of diabetes, Diabetes Metab, vol.25, issue.3, pp.12-20, 1999.

M. Laakso and S. Letho, Epidemiology of macrovascular disease in diabetes, Diabetes Rev, vol.5, pp.294-315, 1997.

W. Kannel and D. Mcgee, Diabetes and cardiovascular risk factors: the Framingham study, Circulation, vol.59, issue.1, pp.8-13, 1979.
DOI : 10.1161/01.CIR.59.1.8

K. Gu, C. Cowie, and M. Harris, Mortality in Adults With and Without Diabetes in a National Cohort of the U.S. Population, 1971-1993, Diabetes Care, vol.21, issue.7, pp.1138-1183, 1998.
DOI : 10.2337/diacare.21.7.1138

R. Klein, Hyperglycemie and Microvascular and Macrovascular Disease in Diabetes, Diabetes Care, vol.18, issue.2, pp.258-68, 1995.
DOI : 10.2337/diacare.18.2.258

P. Rossing, P. Hougaard, K. Borch-johnsen, and H. Parving, Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study, BMJ, vol.313, issue.7060, pp.779-84, 1996.
DOI : 10.1136/bmj.313.7060.779

R. Turner, H. Millns, H. Neil, I. Stratton, S. Manley et al., Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom prospective diabetes study (UKPDS: 23), BMJ, vol.316, issue.7134, pp.823-831, 1998.
DOI : 10.1136/bmj.316.7134.823

T. Matsumoto, Y. Ohashi, N. Yamada, and M. Kikuchi, Coronary Heart Disease Mortality Is Actually Low in Diabetic Japanese by Direct Comparison With the Joslin Cohort, Diabetes Care, vol.17, issue.9, pp.1062-1065, 1994.
DOI : 10.2337/diacare.17.9.1062

L. Niskanen, A. Turpeinen, I. Penttila, and M. Uusitupa, Hyperglycemia and compositional lipoprotein abnormalities as predictors of cardiovascular mortality in type 2 diabetes: a 15-year follow-up from the time of diagnosis, Diabetes Care, vol.21, issue.11, pp.1861-1870, 1998.
DOI : 10.2337/diacare.21.11.1861

C. Semenkovich and J. Heinecke, The Mystery of Diabetes and Atherosclerosis: Time for a New Plot, Diabetes, vol.46, issue.3, pp.327-361, 1997.
DOI : 10.2337/diab.46.3.327

L. Capron, Atherosclerosis and cardio-vascular complications of diabetes], Ann Endocrinol (Paris), vol.57, pp.161-166, 1996.

W. Hsueh, M. Quinones, and M. Creager, Endothelium in insulin resistance and diabetes, Diabetes Rev, vol.5, pp.343-53, 1997.

R. Jokl and J. Colwell, Arterial thrombosis and atherosclerosis in diabetes, Diabetes Rev, vol.5, pp.316-347, 1997.

J. Claude and G. Rosselin, Hypertriglyceridaemia as a risk factor of coronary heart disease mortality in subjects with impaired glucose tolerance or diabetes. Results from the 11-year follow-up of the Paris Prospective Study, Diabetologia, vol.32, pp.300-304, 1989.

M. Laakso, S. Lehto, I. Penttila, and K. Pyorala, Lipids and lipoproteins predicting coronary heart disease mortality and morbidity in patients with non-insulin-dependent diabetes, Circulation, vol.88, issue.4, pp.1421-1451, 1993.
DOI : 10.1161/01.CIR.88.4.1421

H. Hubert, M. Feinleib, P. Mcnamara, and W. Castelli, Obesity as an Independent Risk Factor for Cardiovascular Disease, Survey of Anesthesiology, vol.28, issue.1, pp.968-77, 1983.
DOI : 10.1097/00132586-198402000-00001

L. Lissner, P. Odell, D. Agostino, R. Stokes, J. Kreger et al., Variability of Body Weight and Health Outcomes in the Framingham Population, New England Journal of Medicine, vol.324, issue.26, pp.1839-1883, 1991.
DOI : 10.1056/NEJM199106273242602

A. Rosengren, H. Wedel, and L. Wilhelmsen, Body weight and weight gain during adult life in men in relation to coronary heart disease and mortality A prospective population study, European Heart Journal, vol.20, issue.4, pp.269-77, 1999.
DOI : 10.1053/euhj.1998.1235

S. Yusuf, S. Hawken, S. Ounpuu, T. Dans, A. Avezum et al., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study, The Lancet, vol.364, issue.9438, pp.937-52, 2004.
DOI : 10.1016/S0140-6736(04)17018-9

B. Reeder, L. Liu, and L. Horlick, Selective screening for dyslipidemia in a Canadian population, Journal of Clinical Epidemiology, vol.49, issue.2, pp.217-239, 1996.
DOI : 10.1016/0895-4356(95)00063-1

S. Grover, L. Coupal, and X. Hu, Identifying adults at increased risk of coronary disease. How well do the current cholesterol guidelines work?, JAMA: The Journal of the American Medical Association, vol.274, issue.10, pp.801-807, 1995.
DOI : 10.1001/jama.274.10.801

S. Grover, C. Levinton, and S. Paquet, Identifying Adults at Low Risk for Significant Hyperlipidemia A Validated Clinical Index, Journal of Clinical Epidemiology, vol.52, issue.1, pp.49-55, 1999.
DOI : 10.1016/S0895-4356(98)00139-5

B. Larsson, K. Svardsudd, L. Welin, L. Wilhelmsen, P. Bjorntorp et al., Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913., BMJ, vol.288, issue.6428, pp.1401-1405, 1984.
DOI : 10.1136/bmj.288.6428.1401

I. Lee, J. Manson, C. Hennekens, R. Paffenbarger, and J. , Body weight and mortality. A 27-year follow-up of middle-aged men, JAMA: The Journal of the American Medical Association, vol.270, issue.23, pp.2823-2831, 1993.
DOI : 10.1001/jama.270.23.2823

D. Freedman, D. Williamson, E. Gunter, and T. Byers, Relation of Serum Uric Acid to Mortality and Ischemic Heart Disease, American Journal of Epidemiology, vol.141, issue.7, pp.637-681, 1995.
DOI : 10.1093/oxfordjournals.aje.a117479

M. Stampfer, M. Malinow, W. Willett, L. Newcomer, B. Upson et al., A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians, JAMA: The Journal of the American Medical Association, vol.268, issue.7, pp.877-81, 1992.
DOI : 10.1001/jama.268.7.877

E. Arnesen, H. Refsum, K. Bonaa, P. Ueland, O. Forde et al., Serum Total Homocysteine and Coronary Heart Disease, International Journal of Epidemiology, vol.24, issue.4, pp.704-713, 1995.
DOI : 10.1093/ije/24.4.704

A. Clark and J. Holt, Identifying and managing patients with hyperlipidemia, Am J Manag Care, vol.3, pp.1211-1220, 1997.

E. Ernst and K. Resch, Fibrinogen as a Cardiovascular Risk Factor, Annals of Internal Medicine, vol.118, issue.12, pp.956-63, 1993.
DOI : 10.7326/0003-4819-118-12-199306150-00008

J. Rehm, S. Bondy, C. Sempos, and C. Vuong, Alcohol Consumption and Coronary Heart Disease Morbidity and Mortality, American Journal of Epidemiology, vol.146, issue.6, pp.495-501, 1997.
DOI : 10.1093/oxfordjournals.aje.a009303

R. Klesges, L. Klesges, C. Haddock, and L. Eck, A longitudinal analysis of the impact of dietary intake and physical activity on weight change in adults, Am J Clin Nutr, vol.55, pp.818-840, 1992.

C. Scripture and J. Pieper, Clinical Pharmacokinetics of Fluvastatin, Clinical Pharmacokinetics, vol.67, issue.2, pp.263-81, 2001.
DOI : 10.2165/00003088-200140040-00003

T. Newman, . Kassler-taubkb, and R. Gelarden, Safety of pravastatin in long term clinical trials conducted in united states, J Drug Dev, vol.3, pp.275-280, 1990.

P. Jungnickel, K. Cantral, and P. Maloley, Pravastatin a new drug for the treatment of hypercholesterolemia, Clin Pharm, vol.11, issue.8, pp.677-689, 1992.

G. Plosker and A. Wagstaff, Fluvastatin, Drugs, vol.51, issue.3, pp.433-59, 1996.
DOI : 10.2165/00003495-199651030-00011

H. Yee and N. Fong, Atorvastatin in the Treatment of Primary Hypercholesterolemia and Mixed Dyslipidemias, Annals of Pharmacotherapy, vol.265, issue.4, pp.1030-1073, 1998.
DOI : 10.1161/01.CIR.91.10.2528

A. Dart, G. Jerums, G. Nicholson, M. Emden, I. Hamilton-craig et al., A multicenter, double-blind, one-year study comparing safety and efficacy of atorvastatin versus simvastatin in patients witb hypercholesterolemia, The American Journal of Cardiology, vol.80, issue.1, pp.39-44, 1997.
DOI : 10.1016/S0002-9149(97)00280-4

K. Kivisto, T. Kantola, and P. Neuvonen, Different effects of itraconazole on the pharmacokinetics of fluvastatin and lovastatin, British Journal of Clinical Pharmacology, vol.63, issue.1, pp.49-53, 1998.
DOI : 10.1046/j.1365-2125.1998.00034.x

L. Mccarthy, J. Dlott, A. Orazi, D. Waxman, C. Miraglia et al., Thrombotic Thrombocytopenic Purpura: Yesterday, Today, Tomorrow, Therapeutic Apheresis and Dialysis, vol.70, issue.2, pp.80-86, 2004.
DOI : 10.1182/blood-2003-01-0193

M. Carthy and L. , Thrombotic thrombocytopenic purpura and simvastatin, Lancet, vol.352, pp.1284-1289, 1998.

P. Ames, Simvastatin-induced thrombocytopaenia: a further case and a brief on its clinical relevance, Annals of Hematology, vol.97, issue.9, pp.773-777, 2008.
DOI : 10.1007/s00277-008-0480-1

M. Gonzalez-ponte, Atorvastatin-induced severe thrombocytopenia, The Lancet, vol.352, issue.9136, p.1284, 1998.
DOI : 10.1016/S0140-6736(05)70491-8

I. Vrettos, S. Papageorgiou, C. Economopoulou, V. Pappa, P. Tsirigotis et al., Rosuvastatin-Induced Thrombocytopenia, Southern Medical Journal, vol.103, issue.7, pp.676-684, 2010.
DOI : 10.1097/SMJ.0b013e3181e170f5

. Anonymous, Simvastatin and alopecia, Aust Adverse drug reacr Bull, vol.12, p.7, 1993.

A. Segal, Alopecia associated with atorvastatin, The American Journal of Medicine, vol.113, issue.2, p.171, 2002.
DOI : 10.1016/S0002-9343(02)01135-X

J. Deslypere, Proteinuria as complication of simvastatin treatment, The Lancet, vol.336, issue.8728, p.1453, 1990.
DOI : 10.1016/0140-6736(90)93164-K

H. Martinez-suarez, R. Wang, and G. Faerber, Atorvastatin-Induced Hemorrhagic Cystitis: A Case Report, Urology, vol.73, issue.3, pp.681-686, 2009.
DOI : 10.1016/j.urology.2008.03.027

M. Lechleitner, Depressive symptoms in hypercholesterolaemic patients treated with pravastatin, The Lancet, vol.340, issue.8824, p.910, 1992.
DOI : 10.1016/0140-6736(92)93318-H

N. Duits and F. Bos, Depressive symptoms and cholesterol-lowering drugs, The Lancet, vol.341, issue.8837, p.114, 1993.
DOI : 10.1016/0140-6736(93)92591-G

J. Wardle, Randomised placebo controlled trial of effect on mood of lowering cholesterol concentration, BMJ, vol.313, issue.7049, pp.75-83, 1996.
DOI : 10.1136/bmj.313.7049.75

R. Steward, Long-term Assessment of Psychological Well-being in a Randomized Placebo-Controlled Trial of Cholesterol Reduction With Pravastatin, Archives of Internal Medicine, vol.160, issue.20, pp.3144-52, 2000.
DOI : 10.1001/archinte.160.20.3144

J. Peters, C. Garwood, and M. Lepczyk, Behavioral changes with paranoia in an elderly woman taking atorvastatin, The American Journal of Geriatric Pharmacotherapy, vol.6, issue.1, pp.28-32, 2008.
DOI : 10.1016/j.amjopharm.2008.03.001

L. Galatti, G. Polimeni, F. Salvo, M. Romani, A. Sessa et al., Short-Term Memory Loss Associated with Rosuvastatin, Pharmacotherapy, vol.57, issue.7, pp.1190-1192, 2006.
DOI : 10.1592/phco.2005.25.7.990

D. King, A. Wilburn, M. Wofford, T. Harrell, B. Lindley et al., Cognitive Impairment Associated with Atorvastatin and Simvastatin, Pharmacotherapy, vol.34, issue.12, pp.1663-1670, 2003.
DOI : 10.1001/archinte.160.20.3144

J. Backers and P. Howard, Association of HMG-CoA Reductase Inhibitors with Neuropathy, Annals of Pharmacotherapy, vol.344, issue.2, pp.274-281, 2003.
DOI : 10.1038/clpt.1981.154

. Anonymous, Paresthesia and neuropathy with hypolipidaemia agents, Aust Adverse Drug Reac Bull, vol.12, p.6, 1993.

T. Phan, Peripheral neuropathy associated with simvastatin., Journal of Neurology, Neurosurgery & Psychiatry, vol.58, issue.5, pp.625-633, 1995.
DOI : 10.1136/jnnp.58.5.625

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1073498

U. Jeppesen, Statins and peripheral neuropathy, European Journal of Clinical Pharmacology, vol.54, issue.11, pp.835-843, 1999.
DOI : 10.1007/s002280050562

M. Jacobs, HMG-CoA Reductase Inhibitor Therapy and Peripheral Neuropathy, Annals of Internal Medicine, vol.120, issue.11, p.970, 1994.
DOI : 10.7326/0003-4819-120-11-199406010-00013

I. Abellán-miralles, R. Sánchez-pérez, N. Pérez-carmona, C. Díaz-marín, and J. Mallada-frechín, Multiple mononeuropathy associated to treatment with pravastatin Partina Galandú s/n, E-03570 Villajoyosa, Rev Neurol, vol.43, issue.11, pp.659-61, 2006.

R. Scola, A. Trentin, F. Germiniani, E. Piovesan, and L. Werneck, Simvastatin-induced mononeuropathy multiplex: case report, Arquivos de Neuro-Psiquiatria, vol.62, issue.2b, pp.540-542, 2004.
DOI : 10.1590/S0004-282X2004000300031

URL : http://doi.org/10.1590/s0004-282x2004000300031

G. Fadini, E. Manzato, C. Crepaldi, S. De-kreutzenberg, A. Tiengo et al., Two Cases of Statin-Induced Rhabdomyolysis Associated with Mononeuropathy, Clinical Drug Investigation, vol.166, issue.5, pp.347-50, 2010.
DOI : 10.2165/11535470-000000000-00000

S. Ahn, Neuromuscular Complications of Statins, Physical Medicine and Rehabilitation Clinics of North America, vol.19, issue.1, pp.47-59, 2008.
DOI : 10.1016/j.pmr.2007.10.002

G. Jackson, Drug points: Simvastatin and impotence, BMJ, vol.315, issue.7099, p.31, 1997.
DOI : 10.1136/bmj.315.7099.31a

T. Perderson, Simvastatin seems unlikely to cause impotence, BMJ, vol.318, issue.7177, p.192, 1999.
DOI : 10.1136/bmj.318.7177.192a

. Rizvik, Do lipid-lowering drugs cause erectile dysfunction? A systematic review, Family Practice, vol.19, issue.1, pp.95-103, 2002.
DOI : 10.1093/fampra/19.1.95

J. Barth, Inhibitors of hydroxymethylglutaryl coenzyme A reductase for treating hypercholesterolaemia., BMJ, vol.301, issue.6753, p.669, 1990.
DOI : 10.1136/bmj.301.6753.669-a

D. Black, Sleep Disturbance and HMG CoA Reductase Inhibitors, JAMA: The Journal of the American Medical Association, vol.264, issue.9, p.1105, 1990.
DOI : 10.1001/jama.1990.03450090041020

S. Eckernäs, The effects of simvastatin and pravastatin on objective and subjective measures of nocturnal sleep: a comparison of two structurally different HMG CoA reductase inhibitors in patients with primary moderate hypercholesterolemia, Br J Clin Pharmacol, vol.35, pp.284-293, 1993.

A. Keech, Absence of effects of prolonged simvastatin therapy on nocturnal sleep in a large randomized placebo-controlled study, British Journal of Clinical Pharmacology, vol.151, issue.1, pp.483-90, 1996.
DOI : 10.1111/j.1365-2125.1996.tb00012.x

K. Wachi, K. Ishii, T. Ikehara, M. Shinohara, T. Kawafune et al., A case of acute cholestatic hepatitis associated with fluvastatin sodium, J Med Soc Toho, vol.48, pp.153-161, 2001.

R. Batey and M. Harvey, Cholestasis associated with the use of pravastatin sodium, Med J Aust, vol.176, issue.11, p.561, 2002.

G. Famularo, L. Miele, G. Minisola, and A. Grieco, Liver toxicity of rosuvastatin therapy. Department of Internal Medicine, World J Gastroenterol Feb, vol.2813, issue.8, pp.1286-1294, 2007.

A. Oteri, M. Catania, A. Russo, F. Salvo, L. Giacci et al., Reversible Acute Hepatitis Induced by Rosuvastatin, Southern Medical Journal, vol.101, issue.7, p.768, 2008.
DOI : 10.1097/SMJ.0b013e3181778d75

J. Rahier, J. Rahier, I. Leclercq, and A. Geubel, Severe acute cholestatic hepatitis with prolonged cholestasis and bile-duct injury following atorvastatin therapy: a case report, Acta Gastroenterol Belg, vol.71, issue.3, pp.318-338, 2008.

D. Castro, M. Hermo, J. Baz, A. De-luaces, C. Pérez et al., Hepatitis colest??sica aguda tras la reintroducci??n de atorvastatina, Servicio de Aparato Digestivo, pp.21-25, 2006.
DOI : 10.1157/13083248

E. Ridruejo and O. Mandó, Acute cholestatic hepatitis after reinitiating treatment with atorvastatin, Journal of Hepatology, vol.37, issue.1, pp.165-171, 2002.
DOI : 10.1016/S0168-8278(02)00092-2

S. Singh and Y. Loke, Statins and Pancreatitis, Drug Safety, vol.13, issue.1, pp.1123-1155, 2006.
DOI : 10.2165/00002018-200629120-00004

J. Johnson and I. Loomis, A case of simvastatin-associated pancreatitis and review of statinassociated pancreatitis Department of Pharmacy: Clinical and Administrative Sciences, pp.414-436, 2006.

M. Ramdani, A. Schmitt, J. Liautard, O. Duhamel, P. Legroux et al., Pancréatite aigue à la simvastatine: 2 cas, Gastroenterol Clin Biol, vol.15, issue.12, p.986, 1991.

T. Lons and M. Chousterman, La simvastatine: une nouvelle molécule responsable de pancréatite aigue ?, Gastroenterol Clin Bio, vol.15, issue.1, pp.93-97, 1991.

V. Andersen, J. Sonne, and M. Andersen, Spontaneous reports on drug induced pancreatitisin denmark from 1968 to 1999, Eur J Clin Pharmacol, vol.57, pp.6-7, 2001.

R. Pezzili, R. Ceciliato, R. Corinaldesi, and B. Barakat, Acute pancreatitis due to simvastatin therapy: increased severity after rechallenge, Digestive and Liver Disease, vol.36, issue.9, pp.639-679, 2004.
DOI : 10.1016/j.dld.2004.05.002

C. Tysk, A. Eryani, and A. Shawabkeh, Acute pancreatitis induced by fluvastatin therapy. Department of Medicine, J Clin Gastroenterol, 2002.
DOI : 10.1097/00004836-200211000-00010

S. Singh, A. Nautiyal, and J. Dolan, Recurrent acute pancreatitis possibly induced by atorvastatin and rosuvastatin. Is statin induced pancreatitis a class effect? Department of Internal Medicine, Unity Health System, pp.502-506, 2004.

B. Noël, Lupus erythematosus and other autoimmune diseases related to statin therapy: a systematic review, Journal of the European Academy of Dermatology and Venereology, vol.142, issue.1, pp.17-24, 2007.
DOI : 10.1038/nrd1471

J. Jiménez-alonso, L. Jaimez, J. Sabio, C. Hidalgo, and L. Leon, Atorvastatin-induced reversible positive antinuclear antibodies, The American Journal of Medicine, vol.112, issue.4, pp.329-359, 2002.
DOI : 10.1016/S0002-9343(01)01102-0

L. Gressier, C. Pruvost-balland, L. Dubertret, and M. Viguier, Syndrome d???hypersensibilit?? m??dicamenteuse induit par l???atorvastatine, Annales de Dermatologie et de V??n??r??ologie, vol.136, issue.1, pp.50-53, 2009.
DOI : 10.1016/j.annder.2008.07.063

B. Noël and R. Panizzon, Lupus-Like Syndrome Associated with Statin Therapy, Dermatology, vol.208, issue.3, pp.276-283, 2004.
DOI : 10.1159/000077320

R. Khosla, A. Butman, and D. Hammer, Simvastatin-Induced Lupus Erythematosus, Southern Medical Journal, vol.91, issue.9, pp.873-877, 1998.
DOI : 10.1097/00007611-199809000-00016

Y. Rajabally, V. Varakantam, and R. Abbott, Disorder resembling Guillain-Barr?? syndrome on initiation of statin therapy, Muscle & Nerve, vol.91, issue.5, pp.663-669, 2004.
DOI : 10.1002/mus.20112

M. Sridhar and A. Abdulla, Fatal lupus-like syndrome and ARDS induced by fluvastatin, The Lancet, vol.352, issue.9122, p.114, 1998.
DOI : 10.1016/S0140-6736(98)85019-8

R. Suchak, K. Benson, and V. Swale, Statin-induced Ro/SSa-positive subacute cutaneous lupus erythematosus, Clinical and Experimental Dermatology, vol.43, issue.5, pp.589-91, 2007.
DOI : 10.1159/000077320

D. Groot, R. Willems, L. Dijkman, and J. , Interstitial lung disease with pleural effusion caused by Simvastin, Journal of Internal Medicine, vol.239, issue.4, pp.361-364, 1996.
DOI : 10.1046/j.1365-2796.1996.411762000.x

N. Liscoët-loheac, N. André, F. Couturaud, E. Chenu, J. Quiot et al., Hypersensitivity pneumonitis in a patient taking pravastatin. Département de Médecine interne et Pneumologie, Rev Mal Respir, vol.18, issue.4, pp.426-434, 2001.

I. Kalomenidis, S. Papiris, and S. Loukides, Bilateral pleural effusions associated with pravastatin sodium treatment, European Respiratory Journal, vol.30, issue.5, p.1022, 2007.
DOI : 10.1183/09031936.00087007

J. Aerts, M. Karmochkine, and G. Raguin, Gynecomastia due to pravastatin, Presse Med, p.787, 1999.

K. Hammons, R. Edwards, and W. Rice, Golf-inhibiting gynecomastia associated with atorvastatin therapy. Moses Cone Health System, pp.1165-1173, 2006.
DOI : 10.1592/phco.26.8.1165

A. Oteri, M. Catania, R. Travaglini, A. Russo, S. Giustini et al., Gynecomastia Possibly Induced by Rosuvastatin, Pharmacotherapy, vol.160, issue.4, pp.549-51, 2008.
DOI : 10.1038/clpt.1981.154

M. Anliker and B. Wüthrich, Chronic urticaria to atorvastatin, Allergy, vol.57, issue.4, p.366, 2002.
DOI : 10.1067/mjd.2001.113462

C. Koning, A. Eickert, K. Scharfetter-kochanek, T. Krieg, and N. Hunzelmann, Linear IgA bullous dermatosis induced by atorvastatin, Journal of the American Academy of Dermatology, vol.44, issue.4, pp.689-92, 2001.
DOI : 10.1067/mjd.2001.113462

B. Adcock, L. Hornsby, and K. J. Jenkins, Dermatographism: An adverse effect of atorvastatin, Am Board Fam Pract, vol.14, issue.2, pp.148-51, 2001.

G. Keough, T. Richardson, and W. Grabski, Pravastatin-induced lichenoid drug eruption

D. Mehregan, D. Mehregan, and P. S. Pinkus, Cheilitis due to treatment with simvastatin, Dermatopathology Laboratory, vol.62, issue.4, pp.197-205, 1998.

T. Akahane, K. Mizushige, H. Nishio, H. Fukui, and S. Kuriyama, Atrial fibrillation induced by simvastatin treatment in a 61-year-old man Heart Vessels, pp.157-166, 2003.

A. Goli, A. Goli, R. Byrd, . Jr, and T. Roy, Simvastatin-induced lactic acidosis: A rare adverse reaction?, Clinical Pharmacology & Therapeutics, vol.72, issue.4, pp.461-465, 2002.
DOI : 10.1067/mcp.2002.127943

J. Be?towski, G. Wójcicka, and A. Jamroz-wi?niewska, Adverse Effects of Statins - Mechanisms and Consequences, Current Drug Safety, vol.4, issue.3, pp.209-237, 2009.
DOI : 10.2174/157488609789006949

J. Mercier and A. Lacampagne, New insights into mechanisms of statin-associated myotoxicity

P. Toth, C. Harper, and T. Jacobson, Clinical characterization and molecular mechanisms of statin myopathy, Expert Review of Cardiovascular Therapy, vol.6, issue.7, pp.955-69, 2008.
DOI : 10.1586/14779072.6.7.955

A. Kumar, S. Wong, and G. Andrew, Statin-induced muscular symptoms: a report of 3 cases. Department of Trauma and Orthopaedics, Acta Orthop Belg, vol.74, issue.4, pp.569-72, 2008.

P. Asbach, I. Paetsch, P. Stawowy, B. Sander, and E. Fleck, Statin-associated focal myositis, International Journal of Cardiology, vol.133, issue.1, pp.33-37, 2009.
DOI : 10.1016/j.ijcard.2007.08.109

B. Schalke, Pravastatin-associated inflammatory myopathy, N Engl J Med, vol.327, pp.649-50, 1992.

B. Noel, Atorvastatin-induced dermatomyositis, The American Journal of Medicine, vol.110, issue.8, pp.670-671, 2001.
DOI : 10.1016/S0002-9343(01)00711-2

A. Lea and . Mctavish, Atorvastatin, Drugs, vol.53, issue.5, pp.828-875, 1997.
DOI : 10.2165/00003495-199753050-00011

V. Purvin, A. Kawasaki, K. Smith, and A. Kesler, Statin-Associated Myasthenia Gravis, Midwest Eye Institute, pp.82-87, 2006.
DOI : 10.1097/01.md.0000209337.59874.aa

D. Boltan, W. Lachar, A. Khetan, J. Bouffard, and W. Roberts, Fatal and Widespread Skeletal Myopathy Confirmed Morphologically Years After Initiation of Simvastatin Therapy, The American Journal of Cardiology, vol.99, issue.8, pp.1171-1177, 2007.
DOI : 10.1016/j.amjcard.2006.11.071

M. Justiniano, S. Dold, and L. Espinoza, Rapid Onset of Muscle Weakness (Rhabdomyolysis) Associated With the Combined Use of Simvastatin and Colchicine, JCR: Journal of Clinical Rheumatology, vol.13, issue.5, pp.266-274, 2007.
DOI : 10.1097/RHU.0b013e318156d977

E. Atasoyu, T. Evrenkaya, and E. Solmazgul, Possible colchicine rhabdomyolysis in a fluvastatintreated patient Ann Pharmacother, pp.7-81368, 2005.

E. Molden and K. Andersson, Simvastatin-Associated Rhabdomyolysis After Coadministration of Macrolide Antibiotics in Two Patients, Pharmacotherapy, vol.63, issue.4, pp.603-610, 2007.
DOI : 10.1185/030079905X65466

H. Maltz, D. Balog, and J. Cheigh, Rhabdomyolysis Associated with Concomitant Use of Atorvastatin and Cyclosporine, Annals of Pharmacotherapy, vol.57, issue.11, pp.1176-1185, 1999.
DOI : 10.1056/NEJM199509073331003

L. Gallelli, M. Ferraro, V. Spagnuolo, P. Rende, G. Mauro et al., Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation. Department of Experimental and Clinical Medicine, Faculty of Medicine and Surgery, luca_gallelli@gmail.com. Drug Metabol Drug Interact, vol.24, issue.1, pp.83-90, 2009.

N. Mikhail, E. Iskander, and D. Cope, Rhabdomyolysis in an HIV-Infected Patient on Anti-Retroviral Therapy Precipitated by High-Dose Pravastatin, Current Drug Safety, vol.4, issue.2, pp.121-123, 2009.
DOI : 10.2174/157488609788173080

M. Gama, S. Pellegrinello, S. Alonso, J. Coelho, C. Martins et al., Rabdomi??lise devido ao uso de estatina em altas doses: relato de caso, Arquivos Brasileiros de Endocrinologia & Metabologia, vol.49, issue.4, pp.604-613, 2005.
DOI : 10.1590/S0004-27302005000400021

G. Fadini, E. Manzato, C. Crepaldi, S. De-kreutzenberg, A. Tiengo et al., Rhabdomyolysis as a side effect of simvastatin treatment0, Iskra B, Zivko M, Kes P. Interni odjel Acta Med Croatica, vol.59, issue.4, pp.325-333, 2005.

G. Fadini, E. Manzato, C. Crepaldi, S. De-kreutzenberg, A. Tiengo et al., Two Cases of Statin-Induced Rhabdomyolysis Associated with Mononeuropathy, Clinical Drug Investigation, vol.166, issue.5, pp.347-50, 2010.
DOI : 10.2165/11535470-000000000-00000

C. Schindler, M. Thorns, K. Matschke, S. Tugtekin, and W. Kirch, Asymptomatic statin-induced rhabdomyolysis after long-term therapy with the hydrophilic drug pravastatin, Clinical Therapeutics, vol.29, issue.1, pp.172-178, 2007.
DOI : 10.1016/j.clinthera.2007.01.017

S. Rubí, J. Duch, J. Ortín, X. Setoain, and F. Pons, Rhabdomyolysis after treatment with atorvastatin detected by bone scintigraphy, Hospital Clínic, vol.25, issue.6, p.393, 2006.

F. Lado, R. Moreno, C. , C. Sajurjo, S. et al., Statin-induced rhabdomyolysis and renal failure: also with fluvastatine Servicio de Medicina Interna, An Med Interna, vol.21, issue.5, pp.235-242, 2004.

S. Jamil and P. Iqbal, Rhabdomyolysis induced by a single dose of a statin. Medical Directorate, Chesterfield and North Derbyshire Royal Hospital NHS Calow, p.3, 2004.

K. Baxter, Stockley's Drug interaction. 18 Ed, PhP, vol.12, pp.449-52, 2008.

S. Simonson, Effect of Rosuvastatin on Warfarin Pharmacodynamics and Pharmacokinetics, The Journal of Clinical Pharmacology, vol.58, issue.8, pp.927-961, 2005.
DOI : 10.1177/0091270005278224

P. Ltd, UK Summary of product characteristics Atorvastatin, 2006.

K. Peter and J. Jewitt-harris, Safety and Tolerability of Fluvastatin With Concomitant Use of Antihypertensive Agents: An Analysis of a Clinical Trial Database, American Journal of Hypertension, vol.6, issue.11 Pt 2, pp.346-352, 1993.
DOI : 10.1093/ajh/6.11.346S

N. Azie and D. Brater, The interaction of diltiazem with lovastatin and pravastatin*, Clinical Pharmacology & Therapeutics, vol.318, issue.4, pp.369-77, 1998.
DOI : 10.1016/S0009-9236(98)90067-4

K. Baxter, Stockley's Drug interaction. 18 Ed, PhP, vol.30, p.1096, 2008.

P. Gruer and J. Vega, Concomitant use of cytochrome P450 3A4 inhibitors and simvastatin, The American Journal of Cardiology, vol.84, issue.7, pp.811-826, 1999.
DOI : 10.1016/S0002-9149(99)00442-7

K. Baxter, Stockley's Drug interaction. 18 Ed, PhP, vol.30, p.1092, 2008.

K. Baxter, Stockley's Drug interaction. 18 Ed, PhP, vol.30, p.1099, 2008.

W. Hsu and W. Chen, Colchicine-Induced Acute Myopathy in a Patient With Concomitant Use of Simvastatin, Clinical Neuropharmacology, vol.25, issue.5, pp.226-234, 2002.
DOI : 10.1097/00002826-200209000-00008

A. Alsheikh-ali and R. Karas, Adverse Events With Concomitant Amiodarone and Statin Therapy, Preventive Cardiology, vol.8, issue.2, pp.95-102, 2005.
DOI : 10.1016/S0002-9343(01)00870-1

K. Baxter, Stockley's Drug interaction. 18 Ed, PhP, vol.30, pp.1104-1109, 2008.

K. Baxter, Stockley's Drug interaction. 18 Ed, PhP, vol.30, p.1095, 2008.

M. Sirvent and L. , New insights into mechanisms of statin-associated myotoxicity, Current Opinion in Pharmacology, vol.8, issue.3, pp.333-338, 2008.
DOI : 10.1016/j.coph.2007.12.010